Pharmacology of a Potent and Novel Inhibitor of the NOD-Like Receptor Pyrin Domain-Containing Protein 3 (NLRP3) Inflammasome that Attenuates Development of Nonalcoholic Steatohepatitis and Liver Fibrosis-Reference-Cited by-同舟云学术

Pharmacology of a Potent and Novel Inhibitor of the NOD-Like Receptor Pyrin Domain-Containing Protein 3 (NLRP3) Inflammasome that Attenuates Development of Nonalcoholic Steatohepatitis and Liver Fibrosis

Published:2023-06-12 Issue:2 Volume:386 Page:242-258
ISSN:0022-3565
Container-title:Journal of Pharmacology and Experimental Therapeutics
language:en
Short-container-title:J Pharmacol Exp Ther

Author:

Povero Davide^ORCID,Lazic Milos,McBride Christopher,Ambrus-Aikelin Geza,Stansfield Ryan,Johnson Casey D.,Santini Angelina M.,Pranadinata Rama F.,McGeough Matthew D.,Stafford Jeffrey A.,Hoffman Hal M.,Feldstein Ariel E.,Veal James M.,Bain Gretchen

Publisher

American Society for Pharmacology & Experimental Therapeutics (ASPET)

Subject

Pharmacology,Molecular Medicine

Reference52 articles.

1. NLRP3 inflammasome activation downstream of cytoplasmic LPS recognition by both caspase-4 and caspase-5

2. Boron-Based Inhibitors of the NLRP3 Inflammasome;Baldwin;Cell Chem Biol,2017

3. The NLRP3 inflammasome functions as a driver of the myelodysplastic syndrome phenotype

4. The CANTOS Trial

5. Inflammasome-Mediated Disease Animal Models Reveal Roles for Innate but Not Adaptive Immunity

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Mechanism of epigallocatechin gallate in treating non-alcoholic fatty liver disease: Insights from network pharmacology and experimental validation;Biochemical and Biophysical Research Communications;2024-11

2. The role of pyroptosis in metabolism and metabolic disease;Biomedicine & Pharmacotherapy;2024-07

3. Pharmacological Analysis of NLRP3 Inflammasome Inhibitor Sodium [(1,2,3,5,6,7-Hexahydro-s-indacen-4-yl)carbamoyl][(1-methyl-1H-pyrazol-4-yl)({[(2S)-oxolan-2-yl]methyl})sulfamoyl]azanide in Cellular and Mouse Models of Inflammation Provides a Translational Framework;ACS Pharmacology & Translational Science;2024-04-18

4. Target Cell Activation of a Structurally Novel NOD-Like Receptor Pyrin Domain-Containing Protein 3 Inhibitor NT-0796 Enhances Potency;Journal of Pharmacology and Experimental Therapeutics;2024-01-22

5. Pharmacological targets at the lysosomal autophagy–NLRP3 inflammasome crossroads;Trends in Pharmacological Sciences;2024-01